Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI and quality-of-life outcomes after conversion from MMF to Myfortic in simultaneous pancreas-kidney transplant recipients
2005-001144-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in Pancreas transplant status, sponsored by Novartis. Primary endpoint: Change in patient-reported GI and HRQL questionnaire responses after conversion. Started Jan 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
Pancreas transplant status
Beyond the preview
Go deeper on 2005-001144-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001144-23.